Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

CaroGen and Yale start work on COVID-19 vaccine

Farmington-based CaroGen and scientists from Yale have begun work on a vaccine targeting the coronavirus responsible for the ongoing global outbreak of COVID-19 disease. The...

| By Kelley Gipson

newhavenbiz recognizes 2020 ‘Power 50’

The magazine newhavenbiz recently recognized The Power 50 Class of 2020. I am so proud to be part of the evolution of the bio industry...

| By Kelley Gipson

UConn researcher gets NIH funding re tumor growth

A researcher at the UConn School of Dental Medicine recently received a $2.5 million grant from the National Cancer Institute to further investigate cancer growth...

| By Kelley Gipson

Vanessa appoints Childs Corporate Controller

Vanessa Research has appointed Stephen Childs Corporate Controller, effective March 23, 2020. Childs is a graduate of Quinnipiac University and holds a graduate certificate in Accounting from the...

| By Kelley Gipson

UConn researchers discover bone stem cells

A population of stem cells with the ability to generate new bone has been discovered by a group of researchers at the UConn School of Dental...

| By Kelley Gipson

Yale researchers study liver metabolism

Many health problems in the developed world stem from the disruption of a delicate metabolic balance between glucose production and energy utilization in the liver....

| By Kelley Gipson

Farmington JAX is studying the genome in 3D

Three-dimensional genomic compartments and sub-compartments help regulate gene expression across the genome. As more data comes out about 3D genomic structures, there is an increasing...

| By Kelley Gipson

Sema4 and VieCure collaborate re oncology care

Sema4, a patient-centered health intelligence company, and VieCure, an artificial intelligence informatics company, have announced a strategic collaboration. Through this alliance, Sema4 data scientists will be...

| By Kelley Gipson

Biopharma companies respond to Corona virus

So many companies are doing battle to fight the COVID19 virus. Connecticut companies such as Nanoviricides, working on treatment, and Protein Sciences, working on a vaccine,...

| By Kelley Gipson

Biohaven migraine drug gets FDA green light

The has approved NURTEC™ ODT (rimegepant) for the acute treatment of migraine in adults. NURTEC ODT is the first FDA-approved product for Biohaven. “NURTEC ODT...